Brief: IO Biotech Says Io102-Io103 Combo With Keytruda Shows 55% Orr In Nsclc

IO Biotech

07/11/2024 19:10

Nov 7 (Reuters) - IO Biotech Inc  IOBT.O :
    * IO BIOTECH REPORTS ITS OFF-THE-SHELF THERAPEUTIC CANCER
VACCINE,
IO102-IO103, IN COMBINATION WITH KEYTRUDA® DEMONSTRATES
PROMISING ACTIVITY AND DURABILITY IN FIRST-LINE TREATMENT OF
PATIENTS WITH METASTATIC LUNG CANCER IN PHASE 2 IOB-022 STUDY
    * IO BIOTECH INC - IO102-IO103 COMBO WITH KEYTRUDA SHOWS 55%
ORR
IN NSCLC
    * IO BIOTECH INC - IO102-IO103 COMBO SHOWS NO UNEXPECTED
TOXICITIES

Source text:  ID:nGNXbDF1BH 
Further company coverage:  IOBT.O 

 ((Reuters.Briefs@thomsonreuters.com;))